A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Blinatumomab (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms Horai
- Sponsors Amgen
- 26 Jun 2017 Planned End Date changed from 1 Jul 2020 to 3 Feb 2020.
- 26 Jun 2017 Planned primary completion date changed from 1 Feb 2018 to 24 Aug 2017.
- 26 Jun 2017 Status changed from recruiting to active, no longer recruiting.